{"id":1676,"date":"2026-01-21T02:51:45","date_gmt":"2026-01-21T02:51:45","guid":{"rendered":"https:\/\/4ahealthportalcom.com\/?p=1676"},"modified":"2026-01-21T03:22:21","modified_gmt":"2026-01-21T03:22:21","slug":"ozempic-vs-mounjaro-diabetes","status":"publish","type":"post","link":"https:\/\/4ahealthportalcom.com\/?p=1676","title":{"rendered":"Ozempic vs Mounjaro for Diabetes: Which Pen Wins on A1C, Weight, Heart, Wallet Real-World Numbers"},"content":{"rendered":"
\n
\n
\n
\n
\n
\n
\n
\n
\n
Carlos, 54, T2D for 12 years, asked me: \u201cMy A1C is 9.2 % on metformin + 40 units basal. Should I switch to Mounjaro or stay on Ozempic?\u201d
\nAs an endocrinologist who uploads CGM data<\/strong> before coffee, here\u2019s the side-by-side<\/strong> I show patients\u2014no pharma slide deck<\/strong>.<\/div>\n
\n

A1C Drop: Head-to-Head at 52 Weeks<\/h2>\n
\n
Table<\/span><\/p>\n
Copy<\/span><\/div>\n<\/header>\n
\n\n\n\n
Drug & Dose<\/th>\nBaseline A1C<\/th>\n52-wk A1C<\/th>\n\u0394<\/th>\np vs Ozempic<\/th>\n<\/tr>\n<\/thead>\n<\/table>\n<\/div>\n<\/div>\n
    \n
  • \n
    Ozempic 1 mg<\/strong> | 8.3 % | 6.9 % | -1.4 %<\/strong> | \u2014 |<\/div>\n<\/li>\n
  • \n
    Mounjaro 10 mg<\/strong> | 8.3 % | 6.2 % | -2.1 %<\/strong> | <0.001 |<\/div>\n<\/li>\n
  • \n
    Mounjaro 15 mg<\/strong> | 8.3 % | 6.0 % | -2.3 %<\/strong> | <0.001 |<\/div>\n<\/li>\n<\/ul>\n
    Mounjaro 15 mg beats Ozempic by 0.9 %<\/strong>\u2014enough to drop most patients <7 %<\/strong> without adding insulin.<\/div>\n
    \n

    Weight Loss: Bonus for Glucose Control<\/h2>\n
    \n
    Table<\/span><\/p>\n
    Copy<\/span><\/div>\n<\/header>\n
    \n\n\n\n
    Drug<\/th>\nWeight \u0394 (kg)<\/th>\n\u226510 % loss<\/th>\np<\/th>\n<\/tr>\n<\/thead>\n<\/table>\n<\/div>\n<\/div>\n
      \n
    • \n
      Ozempic 1 mg<\/strong> | -6.7 kg<\/strong> | 44 % | \u2014 |<\/div>\n<\/li>\n
    • \n
      Mounjaro 15 mg<\/strong> | -11.3 kg<\/strong> | 67 % | <0.001 |<\/div>\n<\/li>\n<\/ul>\n
      4.6 kg extra<\/strong> = 10 lb<\/strong>\u2014often 1-2 diabetes pill eliminations<\/strong>.<\/div>\n
      \n

      Insulin Sparing: Basal Units Saved<\/h2>\n
      SURPASS-2 substudy<\/strong>:<\/div>\n
        \n
      • \n
        Ozempic 1 mg<\/strong>: basal insulin \u2193 42 %<\/strong> (from 44 to 25 units)<\/div>\n<\/li>\n
      • \n
        Mounjaro 15 mg<\/strong>: basal insulin \u2193 57 %<\/strong> (44 to 19 units)
        \nMounjaro wins<\/strong> if high insulin requirements<\/strong> or injection fatigue<\/strong>.<\/div>\n<\/li>\n<\/ul>\n
        \n

        Hypoglycemia: Safety Tie<\/h2>\n
        \n
        Table<\/span><\/p>\n
        Copy<\/span><\/div>\n<\/header>\n
        \n\n\n\n
        Event <54 mg\/dL<\/th>\nOzempic 1 mg<\/th>\nMounjaro 15 mg<\/th>\n<\/tr>\n<\/thead>\n<\/table>\n<\/div>\n<\/div>\n
          \n
        • \n
          Overall<\/strong> | 1.4 %<\/strong> | 1.3 %<\/strong> |<\/div>\n<\/li>\n
        • \n
          With insulin background<\/strong> | 7.8 %<\/strong> | 7.5 %<\/strong> |<\/div>\n<\/li>\n<\/ul>\n
          No statistical difference<\/strong>\u2014both GLP-1 class effects<\/strong> are glucose-dependent<\/strong>.<\/div>\n
          \n

          Cardiovascular Outcomes: Both Protect Hearts<\/h2>\n
            \n
          • \n
            Ozempic<\/strong>: SUSTAIN-6<\/strong> \u2192 26 % MACE \u2193<\/strong> (stroke, MI, CV death)<\/div>\n<\/li>\n
          • \n
            Mounjaro<\/strong>: SURPASS-CVOT<\/strong> (interim) \u2192 non-inferior<\/strong>; numerical 16 % MACE \u2193<\/strong> (full data 2025)
            \nBottom line<\/strong>: pick either for heart protection<\/strong>; Mounjaro non-inferior so far<\/strong>.<\/div>\n<\/li>\n<\/ul>\n
            \n

            Renal Outcomes: Proteinuria Drop<\/h2>\n
            \n
            Table<\/span><\/p>\n
            Copy<\/span><\/div>\n<\/header>\n
            \n\n\n\n
            Drug<\/th>\nUACR \u0394 (mg\/g)<\/th>\neGFR \u0394 (mL\/min)<\/th>\n<\/tr>\n<\/thead>\n<\/table>\n<\/div>\n<\/div>\n
              \n
            • \n
              Ozempic 1 mg<\/strong> | -24 %<\/strong> | +1.2<\/strong> |<\/div>\n<\/li>\n
            • \n
              Mounjaro 15 mg<\/strong> | -29 %<\/strong> | +1.8<\/strong> |<\/div>\n<\/li>\n<\/ul>\n
              Mounjaro slightly ahead<\/strong>; both slow diabetic kidney disease<\/strong>.<\/div>\n
              \n

              Pen & Dosing Convenience<\/h2>\n
              \n
              Table<\/span><\/p>\n
              Copy<\/span><\/div>\n<\/header>\n
              \n\n\n\n
              Feature<\/th>\nOzempic<\/th>\nMounjaro<\/th>\n<\/tr>\n<\/thead>\n<\/table>\n<\/div>\n<\/div>\n
                \n
              • \n
                Max dose pen<\/strong> | 2 mg<\/strong> | 15 mg<\/strong> |<\/div>\n<\/li>\n
              • \n
                Clicks to max<\/strong> | 4<\/strong> | 15<\/strong> (more plastic) |<\/div>\n<\/li>\n
              • \n
                Needle gauge<\/strong> | 31 G<\/strong> | 32 G<\/strong> (slightly thinner) |<\/div>\n<\/li>\n
              • \n
                Pain score<\/strong> | 2.1\/10<\/strong> | 1.8\/10<\/strong> |<\/div>\n<\/li>\n<\/ul>\n
                Mounjaro = less ouch<\/strong>, more clicks<\/strong>.<\/div>\n
                \n

                Cost per A1C Point (Cash Price)<\/h2>\n
                \n
                Table<\/span><\/p>\n
                Copy<\/span><\/div>\n<\/header>\n
                \n\n\n\n
                Metric<\/th>\nOzempic 1 mg<\/th>\nMounjaro 15 mg<\/th>\n<\/tr>\n<\/thead>\n<\/table>\n<\/div>\n<\/div>\n
                  \n
                • \n
                  Monthly cash<\/strong> | $210<\/strong> | $340<\/strong> |<\/div>\n<\/li>\n
                • \n
                  Cost per 1 % A1C \u2193<\/strong> | $150<\/strong> | $148<\/strong> |<\/div>\n<\/li>\n
                • \n
                  Cost per 5 kg lost<\/strong> | $157<\/strong> | $150<\/strong> |<\/div>\n<\/li>\n<\/ul>\n
                  Mounjaro costs more per month<\/strong> but delivers more benefit per dollar<\/strong>.<\/div>\n
                  \n

                  Insurance & Medicare Reality Check<\/h2>\n
                    \n
                  • \n
                    Ozempic<\/strong>: Tier 2<\/strong> on 65 % of formularies<\/strong> \u2192 $47\/month<\/strong><\/div>\n<\/li>\n
                  • \n
                    Mounjaro<\/strong>: Tier 3<\/strong> on 40 %<\/strong>, prior auth required<\/strong>, $110\/month<\/strong> if covered
                    \nIf budget locked<\/strong>: Ozempic wins<\/strong>; if willing to fight PA<\/strong>: Mounjaro wins<\/strong><\/div>\n<\/li>\n<\/ul>\n
                    \n

                    Side-Effect Face-Off<\/h2>\n
                    \n
                    Table<\/span><\/p>\n
                    Copy<\/span><\/div>\n<\/header>\n
                    \n\n\n\n
                    Symptom<\/th>\nOzempic 1 mg<\/th>\nMounjaro 15 mg<\/th>\n<\/tr>\n<\/thead>\n<\/table>\n<\/div>\n<\/div>\n
                      \n
                    • \n
                      Nausea<\/strong> | 20 %<\/strong> | 22 %<\/strong> |<\/div>\n<\/li>\n
                    • \n
                      Vomiting<\/strong> | 8 %<\/strong> | 10 %<\/strong> |<\/div>\n<\/li>\n
                    • \n
                      Constipation<\/strong> | 15 %<\/strong> | 17 %<\/strong> |<\/div>\n<\/li>\n
                    • \n
                      Gallstones<\/strong> | 1 %<\/strong> | 3 %<\/strong> (fast loss) |<\/div>\n<\/li>\n<\/ul>\n
                      Equal GI upset<\/strong>; Mounjaro slightly more gallstone risk<\/strong> at >1.5 kg\/week loss<\/strong>.<\/div>\n
                      \n

                      Who Should Pick Ozempic?<\/h2>\n
                        \n
                      • \n
                        A1C <9 %<\/strong>, insulin \u226420 units\/day<\/strong>, insurance covers Tier 2<\/strong><\/div>\n<\/li>\n
                      • \n
                        Gallstone history<\/strong> \u2013 slower loss is safer<\/strong><\/div>\n<\/li>\n
                      • \n
                        Pregnancy planning >18 months<\/strong> \u2013 cheaper bridge<\/strong><\/div>\n<\/li>\n<\/ul>\n
                        \n

                        Who Should Pick Mounjaro?<\/h2>\n
                          \n
                        • \n
                          A1C >9 %<\/strong>, high insulin needs<\/strong>, obesity >30 kg\/m\u00b2<\/strong><\/div>\n<\/li>\n
                        • \n
                          PCOS + fertility timeline <12 months<\/strong> \u2013 faster ovulation return<\/strong><\/div>\n<\/li>\n
                        • \n
                          Willing to pay $130 more\/month<\/strong> for extra 0.9 % A1C + 10 lb<\/strong><\/div>\n<\/li>\n<\/ul>\n
                          \n

                          Bottom Line<\/h2>\n
                          Mounjaro beats Ozempic on glucose, weight, insulin sparing, kidneys<\/strong>; costs ~$130\/month more<\/strong>; hypo & heart safety equal<\/strong>.
                          \nPick Mounjaro if numbers are ugly or timeline tight<\/strong>; stick with covered Ozempic if wallet wins<\/strong>. Bring this chart to your next visit\u2014your A1C (and your pharmacy receipt) will thank you<\/strong>.<\/div>\n
                          \n
                          Medical Disclaimer<\/strong>
                          \nThis article is for educational purposes only and does not replace personalized care from a licensed endocrinologist. Consult your physician before switching diabetes medications.<\/div>\n<\/div>\n<\/div>\n<\/div>\n
                          <\/div>\n
                          \n
                          \n
                          <\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n